TherapeuticsMD (TXMD) FCF Margin (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly FCF Margin came in at 89.64% in Q2 2026, up 4962.0% on a YoY basis from 1.77% in Q2 2025, and down 31.25% quarter-over-quarter from 130.39% in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) FCF Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported FCF Margin for 16 consecutive years, with 89.64% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin rose 4962.0% year-over-year to 89.64%; the trailing twelve-month figure through Jun 2026 stood at 94.71% (up 5462.0% YoY), and the FY2025 full-year result was 81.2%, up 1476.0% from the prior year.
- FCF Margin slipped to 89.64% in Q2 2026 per TXMD's latest filing, from 130.39% in the prior quarter.
- Across five years, FCF Margin topped out at 5004.52% in Q3 2022 and bottomed at 10013.21% in Q3 2023.
- Historically, FCF Margin has averaged 920.39% across 5 years, with a median of 17.77% in 2022.
- The sharpest annual moves came in 2023 and 2024: FCF Margin sank 1501773 bps in 2023, then jumped 1000023 bps in 2024.
- Over 5 years, FCF Margin stood at 32.99% in 2022, then sank by 4490 bps to 1448.41% in 2023, then surged by 100 bps to 2.55% in 2024, then surged by 1548 bps to 41.99% in 2025, then surged by 113 bps to 89.64% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 89.64%, 130.39%, and 41.99% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 2.01% |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 23.80% |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 25.52% |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 25.68% |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 89.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 89.64% |
| Mar 31, 2026 | 130.39% |
| Dec 31, 2025 | 41.99% |
| Sep 30, 2025 | 127.42% |
| Jun 30, 2025 | 40.02% |
| Mar 31, 2025 | 177.86% |
| Dec 31, 2024 | 2.55% |
| Sep 30, 2024 | -12.98% |
| Jun 30, 2024 | 620.94% |
| Mar 31, 2024 | -73.16% |
| Dec 31, 2023 | -1,448.41% |
| Sep 30, 2023 | -10,013.21% |
| Jun 30, 2023 | -665.68% |
| Mar 31, 2023 | -2,096.15% |
| Dec 31, 2022 | 32.99% |
| Sep 30, 2022 | 5,004.52% |
| Jun 30, 2022 | -5,948.28% |
| Mar 31, 2022 | -2,577.55% |
| Dec 31, 2021 | 257.00% |
| Sep 30, 2021 | -150.17% |